Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Gross Profit (2020 - 2026)

Longeveron (LGVN) posted quarterly Gross Profit of $264000.0 for Q1 2026, down 4.0% year-over-year from $275000.0 in Q1 2025, and up 2.72% quarter-over-quarter from $257000.0 in Q4 2025.

Longeveron (LGVN) Gross Profit (2020 - 2026) Analysis & Trends

Longeveron's Gross Profit history runs 7 years deep, the most recent figure standing at $264000.0 for Q1 2026.

  • In Q1 2026, Gross Profit fell 4.0% year-over-year to $264000.0; the TTM figure through Mar 2026 stood at $792000.0 (down 56.74% YoY), while the FY2025 annual figure was $803000.0, down 57.38% from the prior year.
  • Gross Profit for Q1 2026 stood at $264000.0, up from $257000.0 in the prior quarter.
  • The five-year high for Gross Profit was $682000.0 in Q3 2024, with the low at -$55000.0 in Q4 2022.
  • The 5-year median for Gross Profit is $160000.0 (2022), against an average of $207941.2.
  • The sharpest annual moves came in 2022 and 2024: Gross Profit tumbled 179.71% in 2022, then soared 26600.0% in 2024.
  • Longeveron's Gross Profit stood at -$55000.0 in 2022, then surged by 96.36% to -$2000.0 in 2023, then jumped by 26600.0% to $530000.0 in 2024, then tumbled by 51.51% to $257000.0 in 2025, then gained by 2.72% to $264000.0 in 2026.
  • Business Quant data shows LGVN's Gross Profit at $264000.0 in Q1 2026, $257000.0 in Q4 2025, and $125000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 182,000.00
Jun 30, 2026 182,000.00
Mar 31, 2026 264,000.00
Mar 31, 2026 264,000.00
Dec 31, 2025 257,000.00
Dec 31, 2025 257,000.00
Sep 30, 2025 125,000.00
Sep 30, 2025 125,000.00
Jun 30, 2025 146,000.00
Jun 30, 2025 146,000.00
Mar 31, 2025 275,000.00
Mar 31, 2025 275,000.00
Dec 31, 2024 530,000.00
Dec 31, 2024 530,000.00
Sep 30, 2024 682,000.00
Sep 30, 2024 682,000.00
Jun 30, 2024 344,000.00
Jun 30, 2024 344,000.00
Mar 31, 2024 329,000.00
Mar 31, 2024 329,000.00